Cocrystal Pharma Advances One Of Its COVID-19 Antiviral Treatment Candidate

  • Cocrystal Pharma Inc COCP selected CDI-988 for clinical development as an oral treatment for COVID-19
  • CDI-988 targeted a highly conserved region in the active site of SARS-CoV-2 main (3CL) protease required for viral replication and was specifically designed and developed as an oral antiviral candidate for COVID-19 using Cocrystal's proprietary structure-based drug discovery platform technology.
  • In January 2022, the Company announced its intention to evaluate two oral protease inhibitors before selecting a lead candidate for clinical development
  • Both CDI-988 and the other candidate exhibited superior in vitro potency and broad-spectrum antiviral activity against SARS-CoV-2 and other coronaviruses. In preclinical studies, both candidates demonstrated favorable safety profiles and pharmacokinetic properties supportive of oral administration for the treatment of COVID-19.
  • "Upon completion of IND-enabling toxicology studies of CDI-988, we plan to file for regulatory approval to begin a first-in-human trial in Australia in the first quarter of 2023," said Sam Lee, Cocrystal's President and co-interim CEO.
  • Price Action: COCP shares are down 4.31% at $2.63 on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefsCOVID-19 Coronavirus
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!